ARTICLE | Clinical News

Yondelis trabectedin regulatory update

November 9, 2009 8:00 AM UTC

PharmaMar said the European Commission approved an expanded label for Yondelis trabectedin in combination with doxorubicin to include the treatment of relapsed platinum-sensitive ovarian cancer. The cytotoxic alkaloid that binds the minor groove of DNA already is approved in the EU to treat soft tissue sarcoma (STS). PharmaMar is a subsidiary of Zeltia S.A. (Madrid:ZEL, Madrid, Spain). Caelyx ( Doxil - U.S.) doxorubicin is marketed by Johnson & Johnson and Schering-Plough Corp., a subsidiary of Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.). ...